The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside [Yahoo! Finance]
Opus Genetics, Inc. (IRD)
Company Research
Source: Yahoo! Finance
With key clinical data still to come, huge financial burn, and valuation almost entirely dependent on trial outcomes, these companies only offer massive upside if everything goes as planned. Here are two of the riskiest biotech stocks investors are betting on. Opus Genetics (IRD) has emerged as one of the boldest and riskiest bets investors are making right now. Valued at $1.4 billion, Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies to restore vision and prevent blindness in people with inherited retinal diseases (IRDs). 5 "Best of the Best" Dividend Stocks to Own in 2026 This 1 Lesser-Known Stock Is Set to Dominate with Nvidia and Broadcom in 2026 Nike, Tilray, and Palantir: Their Unusually Active Put Options Will Boost Your Wallet After Christmas Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Opus stock has surged 60.3%
Show less
Read more
Impact Snapshot
Event Time:
IRD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRD alerts
High impacting Opus Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
IRD
News
- Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Opus Genetics to Present at the J.P. Morgan 2026 Healthcare ConferenceGlobeNewswire
- Opus Genetics (NASDAQ:IRD) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.MarketBeat
- Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best DiseaseGlobeNewswire
- Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
IRD
Sec Filings
- 12/19/25 - Form 8-K
- 12/11/25 - Form SCHEDULE
- 12/11/25 - Form 4
- IRD's page on the SEC website